Yawara Kawano

List of Publications by Year in descending order

72 papers	1,694 citations	361045 20 h-index	301761 39 g-index
77 all docs	77 docs citations	77 times ranked	2931 citing authors

#	Article	IF	Citations
1	A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis in multiple myeloma cells. Biochemical and Biophysical Research Communications, 2022, 587, 153-159.	1.0	9
2	Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma. British Journal of Haematology, 2022, 198, .	1.2	2
3	Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. International Journal of Hematology, 2022, 116, 553-562.	0.7	2
4	Water Droplet-in-Oil Digestion Method for Single-Cell Proteomics. Analytical Chemistry, 2022, 94, 10329-10336.	3.2	6
5	Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood, 2021, 137, 2360-2372.	0.6	26
6	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discovery, 2021, 2, 338-353.	2.6	8
7	Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma. Blood Cancer Discovery, 2021, 2, 370-387.	2.6	19
8	Expression of activated integrin Î²7 in multiple myeloma patients. International Journal of Hematology, 2021, 114, 3-7.	0.7	8
9	Isatuximab plus carfilzomib and dexamethasone in east Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.. Journal of Clinical Oncology, 2021, 39, e20015-e20015.	0.8	0
10	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet, The, 2021, 397, 2361-2371.	6.3	177
11	Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis. Cancers, 2021, 13, 5674.	1.7	1
12	The Role of CD38 in Multiple Myeloma Cell Biology. Blood, 2021, 138, 1580-1580.	0.6	0
13	Myeloma Mouse Models in Studying Myeloma-Associated Bone Disease. , 2020, , 355-361.		0
14	Clinical potential of dual-energy cardiac CT in cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 91-92.	1.4	1
15	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Advances, 2019, 3, 995-1002.	2.5	15
16	Roundabout 1 (ROBO1) Mediates Multiple Myeloma Survival and Interaction with the Bone Marrow Microenvironment. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e103-e104.	0.2	0
17	Progression signature underlies clonal evolution and dissemination of Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e19-e20.	0.2	0
18	Base-to-apex gradient pattern of cardiac impairment identified on myocardial T1 mapping in cardiac amyloidosis. Radiology Case Reports, 2019, 14, 72-74.	0.2	3

#	Article	IF	Citations
19	JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib. Blood, 2019, 134, 1814-1814.	0.6	1
20	The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche. Blood, 2019, 134, 507-507.	0.6	0
21	Targeting the Plasma Cell Specific Purine Metabolic Enzyme, AMPD1, Induces Multiple Myeloma Cell Death Accompanying NAD Depletion. Blood, 2019, 134, 3097-3097.	0.6	0
22	Targeting Nicotinamide Adenine Dinucleotide (NAD) Glycohydrase Activity of CD38 Exerts Anti-Myeloma Effect Accompanying Intracellular NAD Elevation. Blood, 2019, 134, 1810-1810.	0.6	1
23	Bufalin induces DNA damage response under hypoxic condition in myeloma cells. Oncology Letters, 2018, 15, 6443-6449.	0.8	6
24	Platelets Enhance Multiple Myeloma Progression via IL-1Î² Upregulation. Clinical Cancer Research, 2018, 24, 2430-2439.	3.2	44
25	MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells. Biochemical and Biophysical Research Communications, 2018, 507, 246-252.	1.0	4
26	Rare concurrent indolent B-cell lymphoma and plasmablastic transformation of myeloma. Journal of Clinical and Experimental Hematopathology: JCEH, 2018, 58, 175-179.	0.3	1
27	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia, 2018, 32, 1739-1750.	3.3	34
28	Blocking IFNAR1 inhibits multiple myelomaâ€“driven Treg expansion and immunosuppression. Journal of Clinical Investigation, 2018, 128, 2487-2499.	3.9	80
29	The Purine Metabolic Enzyme AMPD1 Is a Novel Therapeutic Target for Multiple Myeloma. Blood, 2018, 132, 5614-5614.	0.6	2
30	Role of Noninvasive Diagnostic Imaging in Cardiac Amyloidosis: A Review. Cardiovascular Imaging Asia, 2018, 2, 97.	0.1	4
31	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. Blood, 2018, 132, 55-55.	0.6	0
32	A novel in vivo model for studying conditional dual loss of BLIMPâ€1 and p53 in Bâ€cells, leading to tumor transformation. American Journal of Hematology, 2017, 92, E138-E145.	2.0	3
33	Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. Current Osteoporosis Reports, 2017, 15, 499-506.	1.5	23
34	Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice. Endocrinology, 2017, 158, 3369-3385.	1.4	54
35	Multiple Myeloma and the immune microenvironment. Current Cancer Drug Targets, 2017, 17, 1-1.	0.8	59
36	Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Current Opinion in Hematology, 2016, 23, 426-433.	1.2	33

#	Article	IF	Citations
37	Exome sequencing reveals recurrent germ line variants in patients with familial WaldenstrÃ¶m macroglobulinemia. Blood, 2016, 127, 2598-2606.	0.6	22
38	Epigenetics in Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 35-49.	0.2	7
39	Targeting the Bone Marrow Microenvironment. Cancer Treatment and Research, 2016, 169, 63-102.	0.2	12
40	Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia, 2016, 30, 1103-1115.	3.3	46
41	Abstract 679: Dual conditional loss of BLIMP-1 and p53 in B-cells drives B-cell lymphomagenesis. , 2016, , .		0
42	Roundabout 1 (ROBO1)/SLIT2 Is a Novel Signaling Pathway in Multiple Myeloma Promoting Survival and Bone Marrow Niche Interaction. Blood, 2016, 128, 485-485.	0.6	0
43	Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. Blood, 2016, 128, 4483-4483.	0.6	0
44	Dual Conditional Loss of BLIMP-1 and p53 in B-Cells Drives B-Cell Lymphomagenesis. Blood, 2016, 128, 4169-4169.	0.6	0
45	In Vivo Analysis of Clonal Evolution of Multiple Myeloma. Blood, 2016, 128, 799-799.	0.6	0
46	Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells. International Journal of Oncology, 2015, 46, 963-972.	1.4	62
47	Successful Treatment of Bing-Neel Syndrome Accompanying WaldenstrÃ¶mâ€™s Macroglobulinemia with R-MPV: A Case Report. Journal of Clinical and Experimental Hematopathology: JCEH, 2015, 55, 113-119.	0.3	6
48	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports, 2015, 12, 622-635.	2.9	123
49	The cancer glycome: Carbohydrates as mediators of metastasis. Blood Reviews, 2015, 29, 269-279.	2.8	91
50	Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1. Experimental Hematology and Oncology, 2015, 4, 12.	2.0	40
51	Targeting the bone marrow microenvironment in multiple myeloma. Immunological Reviews, 2015, 263, 160-172.	2.8	323
52	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. Blood, 2015, 126, 502-502.	0.6	4
53	Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma. Blood, 2015, 126, 1793-1793.	0.6	1
54	Clonal-Heterogeneity and Propensity for Bone Metastasis in Multiple Myeloma. Blood, 2014, 124, 3370-3370.	0.6	1

#	Article	IF	Citations
55	Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma. Blood, 2014, 124, 3431-3431.	0.6	8
56	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. Blood, 2014, 124, 2051-2051.	0.6	1
57	Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells. Blood, 2014, 124, 3430-3430.	0.6	0
58	Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression. Blood, 2014, 124, 4719-4719.	0.6	0
59	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. Blood, 2014, 124, 2056-2056.	0.6	0
60	PDK1 inhibition is a novel therapeutic target in multiple myeloma. British Journal of Cancer, 2013, 108, 170-178.	2.9	113
61	PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells. Blood, 2013, 121, 962-970.	0.6	39
62	Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells. International Journal of Oncology, 2013, 43, 1809-1816.	1.4	43
63	Lactate Is a Crucial Energy Source For Multiple Myeloma (MM) Cells In Bone Marrow Microenvironment. Blood, 2013, 122, 3109-3109.	0.6	2
64	A Small Molecule, Shikonin, Dually Functions As a Proteasome Inhibitor and a Necroptosis Inducer In Multiple Myeloma Cells. Blood, 2013, 122, 3172-3172.	0.6	2
65	TRAIL produced from multiple myeloma cells is associated with osteolytic markers. Oncology Reports, 2012, 27, 39-44.	1.2	13
66	Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. International Journal of Oncology, 2012, 41, 876-884.	1.4	84
67	Hypoxia Reduces CD138 Expression and Induces Immature Phenotype in Myeloma Cells. Blood, 2012, 120, 3956-3956.	0.6	0
68	Aerobic Glycolysis: A Possible Target for Treating Multiple Myeloma (MM) with High Serum LDH Levels. Blood, 2011, 118, 1799-1799.	0.6	2
69	Decreased CD138 Expression in Myeloma Cells: A Potential Indicator of Poor Prognosis and Aberrant Differentiation,. Blood, 2011, 118, 3939-3939.	0.6	1
70	Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. Journal of the Neurological Sciences, 2010, 297, 101-104.	0.3	12
71	CD125-Expressing Myeloma: A Subgroup of Multiple Myeloma (MM) with Immature Phenotype, Endoplasmic Reticulum Stress Response and Low Sensitivity to Bortezomib. Blood, 2010, 116, 616-616.	0.6	0
72	Production of TRAIL by Multiple Myeloma Cells: a Potential Prediction Marker for Skeletal-Related Events. Blood, 2010, 116, 2975-2975.	0.6	9